Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Health Care & Life Sciences
Articles
$60M Lilly Endowment grant to fund IU physician research
Indiana University, which has received nearly $600 million from the endowment over the last three decades, will leverage the
new gift to increase its
scientific discoveries and commercialize life science innovations.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Dormir acquires two sleep companies
Carmel firm using $12 million in venture capital for buying spree is now nation’s second-largest operator of sleep centers.
Lilly charity gives $1M to new IU health school
The Eli Lilly and Co. Foundation has given Indiana University $1 million to start a school of public health at Indiana University-Purdue
University Indianapolis.
Noble of Indiana to provide in-home services to disabled
The service will launch in February. Its goal is to serve 15 clients by June 30, 2010.
Health care reform would push state to hike Medicaid pay to docs
An actuarial report prepared by the local office of Milliman Inc., a Seattle-based consulting firm, projects
that the state of Indiana would have to hike its Medicaid payments by one-third in order to entice more
doctors into the program.
Plainfield’s MD Logistics sued by Bristol-Myers over lost insulin
Two semi-trailers of the medication were stolen in 2007 from a back lot at Daum Trucking, which isn’t named in the lawsuit.
Bristol-Myers charges MD Logistics with negligence in the $10.7 million suit.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
HealthNet lands $10.5 million in stimulus funds
HealthNet said it will use the funds to expand and renovate two community health centers that have outgrown their space.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Company’s medical device earns expedited review
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Legislators could test drugmakers’ support for health overhaul
The pharmaceutical industry may have to cough up more than the $80 billion it agreed to contribute to President Barack Obama’s
health overhaul effort, reflecting pressure from Democrats and their supporters for more money to cover older and low-income
people.
Health reform provision called ‘death sentence’ for doctor-owned hospitals
House and Senate versions of health care reform could halt the trend toward physician-owned hospitals.
Health care reform could drive more people to buy their own insurance
If Congress passes health care reform, more people will become like Juli Erhart-Graves, whose family spends nearly 18 percent
of its income on health insurance and out-of-pocket medical costs.
Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Hoosiers ‘waste’ $2.5B a year on health care, group says
Analysis of Medicare data finds that Indiana hospitals and doctors rack up higher costs to treat the same conditions as the
nation’s model markets.
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.